Associated Papers
Clonal architecture of FLT3-ITD and acquired 13q uniparental disomy define prognostic heterogeneity and therapeutic vulnerabilities in acute myeloid leukemia.
Lai A et al.
Neoplasia (new York, N.y.), 2025
41411742 (PubMed )
Supplement: mmc2.xlsx › Sheet1
Uncommon Evolution From Acute Myeloid Leukaemia to JAK2-Mutated Myeloproliferative Neoplasm: Evidence of Clonal Persistence and Divergence From TET2/SRSF2-Mutated Haematopoietic Progenitors.
Turingan MA et al.
Ejhaem, 2025
JAK2 p.R564 germ line variants associated with hereditary thrombocythemia and hematologic neoplasms.
Stewart BL et al.
Blood Advances, 2025
Mutated DNMT3A creates a public HLADQ- binding neoantigen on acute myeloid leukemia.
van der Lee DI et al.
Frontiers in Immunology, 2025
40151616 (PubMed )
Supplement: DataSheet1.docx
Molecular and clinical analyses of PHF6 mutant myeloid neoplasia provide their pathogenesis and therapeutic targeting.
Kubota Y et al.
Nature Communications, 2024
38418452 (PubMed )
Supplement: 41467_2024_46134_MOESM5_ESM.xlsx › Supplementary_Data_2
TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expression.
Heyes E et al.
Nature Communications, 2023
37794021 (PubMed )
Supplement: 41467_2023_41927_MOESM1_ESM.pdf
Deep genomic characterization highlights complexities and prognostic markers of pediatric acute myeloid leukemia.
Cheng CK et al.
Communications Biology, 2023
37002311 (PubMed )
Supplement: 42003_2023_4732_MOESM5_ESM.xlsx › Supplementary_Data_2
SmMIP-tools: a computational toolset for processing and analysis of single-molecule molecular inversion probes-derived data.
Medeiros JJF et al.
Bioinformatics (oxford, England), 2022
35150236 (PubMed )
Supplement: btac081_supplementary_data.zip › Table_S4.xlsx › Clinically_reported_Indels
Technological Advances: CEBPA and FLT3 Internal Tandem Duplication Mutations Can be Reliably Detected by Next Generation Sequencing.
Akabari R et al.
Genes, 2022
Mutational Landscape of CEBPA in Mexican Pediatric Acute Myeloid Leukemia Patients: Prognostic Implications.
Molina Garay C et al.
Frontiers in Pediatrics, 2022
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project
Sargas C et al.
Haematologica, 2021
33179471 (PubMed )
Supplement: 2020_263806_SARGAS_SUPPL.pdf
Germline pathogenic variants in transcription factors predisposing to pediatric acute myeloid leukemia: results from the French ELAM02 trial.
Fenwarth L et al.
Haematologica, 2021
32554555 (PubMed )
Supplement: 2020_248872_FENWARTH_SUPPL.pdf
Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasms.
Rosenthal SH et al.
Plos One, 2021
33909614 (PubMed )
Supplement: pone.0243683.s002.xlsx › S2
Companion gene mutations and their clinical significance in AML with double mutant CEBPA.
Zhang Y et al.
Cancer Gene Therapy, 2020
CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features.
Mannelli F et al.
Haematologica, 2017
Select a paper to view details